Author

G. N. Sapkal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:human· 4 Assay:proteomics· 3 Organism:mouse· 2 Research Focus:differential expression· 1 Organism:rat· 1 Approach:statistical model· 1

Frequent Co-Authors

N. Gupta· 5 shared D. Y. Patil· 4 shared P. Abraham· 4 shared P. Yadav· 4 shared A. M. Shete· 3 shared B. Bhargava· 3 shared R. R. Sahay· 3 shared S. Panda· 3 shared

Activity by Year

2018-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

N. Gupta

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Low immune response after 1.5 years of primary SARS-CoV-2 infection and Covishield vaccination lead to SARS-CoV-2 reinfection

A. M. Shete, D. Y. Patil, R. R. Sahay, G. N. Sapkal, G. R. Deshpande, P. Yadav

The paper examines six cases of SARS-CoV-2 reinfection following primary infection and Covishield vaccination, showing reduced hybrid immunity and the need for booster doses.

bioRxiv · May 12, 2022 · PreprintMicrobiology

Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1

P. Yadav, G. N. Sapkal, P. Abraham, G. Deshpande, D. Nyayanit, D. Y. Patil, N. Gupta, R. R. Sahay, A. Shete, S. Kumar, S. Panda, B. Bhargava

This study compares neutralizing antibody responses in Covishield-vaccinated individuals and COVID-19 recovered subjects against B.1 and B.1.617.1 variants, finding higher neutralization in recovered subjects.

Clinical Infectious Diseases · May 24, 2021Peer-reviewedImmunology

SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant

P. D. Yadav, S. Mohandas, A. M. Shete, D. A. Nyayanit, N. Gupta, D. Y. Patil, G. N. Sapkal, V. Potdar, M. Kadam, A. kumar, S. Kumar, D. Suryavanshi, C. S. Mote, P. Abraham, S. Panda, B. Bhargava

This study compares the pathogenicity of SARS-CoV-2 variants B.1 and B.1.617.1 in hamsters, finding B.1.617.1 causes greater body weight loss, higher viral load, and more severe lung lesions.

bioRxiv · May 5, 2021 · PreprintMicrobiology

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

P. Yadav, G. N. Sapkal, P. Abraham, R. Ella, G. Deshpande, D. Y. Patil, D. Nyayanit, N. Gupta, R. R. Sahay, A. M. Shete, S. Panda, B. Bhargava, V. K. Mohan

The paper assesses the neutralizing ability of sera from BBV152 vaccinees and convalescent COVID-19 patients against B.1.617 variants.

bioRxiv · Apr 23, 2021Immunology

Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152

B. Ganneru, H. Jogdand, V. K. Dharam, N. Reddy, S. D. Prasad, S. Vellimudu, K. M. Ella, R. Ravikrishnan, A. Awasthi, J. Jose, P. Rao, D. Kumar, R. Ella, P. Abraham, P. Yadav, , K. V. Mohan

This study evaluates the safety and immunogenicity of a SARS-CoV-2 vaccine BBV152 in mice, rats, and rabbits, showing high antibody titers and Th1-biased responses with the TLR7/8 agonist adjuvant.

bioRxiv · Sep 9, 2020 · PreprintImmunology

Comparison of two commercial ELISA kits for detection of rubella specific IgM and IgG antibodies

R. Viswanathan, S. George, M. V. Murhekar, A. M. Abraham, M. P. Singh, S. Jadhav, V. Nag, S. Naik, C. G. Raut, A. Munivenkatappa, M. Gupta, V. Jagtap, O. Kaduskar, N. Gupta, G. N. Sapkal

This study compares two ELISA kits for detecting rubella-specific IgM and IgG antibodies, finding good qualitative agreement and suggesting Euroimmun as a viable alternative.

bioRxiv · Apr 21, 2018Microbiology